1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Ophthalmoplegia, Progressive Supranuclear in 1 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villares, J | 1 |
| Faucheux, B | 1 |
| Herrero, MT | 1 |
| Obeso, JA | 1 |
| Duyckaerts, C | 1 |
| Hauw, JJ | 1 |
| Agid, Y | 1 |
| Hirsch, EC | 1 |
1 other study available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Ophthalmoplegia, Progressive Supranuclear
| Article | Year |
|---|---|
[125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Brain | 1998 |